JP2019503348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503348A5 JP2019503348A5 JP2018530797A JP2018530797A JP2019503348A5 JP 2019503348 A5 JP2019503348 A5 JP 2019503348A5 JP 2018530797 A JP2018530797 A JP 2018530797A JP 2018530797 A JP2018530797 A JP 2018530797A JP 2019503348 A5 JP2019503348 A5 JP 2019503348A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- amino acid
- molecule
- kda
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001223 polyethylene glycol Polymers 0.000 claims description 133
- 102000003812 Interleukin-15 Human genes 0.000 claims description 107
- 108090000172 Interleukin-15 Proteins 0.000 claims description 107
- 239000002202 Polyethylene glycol Substances 0.000 claims description 65
- 125000000539 amino acid group Chemical group 0.000 claims description 53
- 238000006467 substitution reaction Methods 0.000 claims description 38
- 125000005647 linker group Chemical group 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 125000003277 amino group Chemical group 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 16
- 230000004988 N-glycosylation Effects 0.000 claims description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000013595 glycosylation Effects 0.000 claims description 8
- 238000006206 glycosylation reaction Methods 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- -1 succinimidyl Chemical group 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 102000056003 human IL15 Human genes 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 5
- 239000004698 Polyethylene Substances 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270447P | 2015-12-21 | 2015-12-21 | |
| US62/270,447 | 2015-12-21 | ||
| PCT/US2016/067042 WO2017112528A2 (en) | 2015-12-21 | 2016-12-15 | Interleukin-15 compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019503348A JP2019503348A (ja) | 2019-02-07 |
| JP2019503348A5 true JP2019503348A5 (cg-RX-API-DMAC7.html) | 2020-01-30 |
Family
ID=59091160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530797A Withdrawn JP2019503348A (ja) | 2015-12-21 | 2016-12-15 | インターロイキン−１５組成物及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180360977A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3393486A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019503348A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180089516A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108472324A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016378387A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018012262A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007819A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL259919A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018007304A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017112528A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201803875B (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639845B1 (en) * | 2017-07-25 | 2023-06-21 | Jiangsu Hengrui Medicine Co., Ltd. | Il-15 protein complex pharmaceutical composition and uses thereof |
| TWI834636B (zh) * | 2018-02-26 | 2024-03-11 | 美商欣爍克斯公司 | Il-15結合物及其用途 |
| CN112533629A (zh) | 2018-06-19 | 2021-03-19 | 阿尔莫生物科技股份有限公司 | 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法 |
| JP7611136B2 (ja) * | 2018-11-09 | 2025-01-09 | ネクター セラピューティクス | 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬 |
| SG11202111175YA (en) * | 2019-04-26 | 2021-11-29 | Prolynx Llc | Slow-release cytokine conjugates |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| WO2021030688A1 (en) * | 2019-08-15 | 2021-02-18 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| CN114555632A (zh) * | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| CN118251495A (zh) * | 2021-11-26 | 2024-06-25 | 杰科（天津）生物医药有限公司 | 一种蛋白的生产方法及其应用 |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN117510828A (zh) * | 2022-07-28 | 2024-02-06 | 厦门赛诺邦格生物科技股份有限公司 | 一种含氨基酸残基的三臂聚乙二醇衍生物 |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE516305T1 (de) * | 2004-02-27 | 2011-07-15 | Inst Nat Sante Rech Med | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
| AR050693A1 (es) * | 2004-08-11 | 2006-11-15 | Zheng Xin Xiao | Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune. |
| JP2008515896A (ja) * | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| MX2017004838A (es) * | 2014-10-14 | 2017-10-16 | Armo Biosciences Inc | Composiciones de interleucina-15 y usos de estas. |
-
2016
- 2016-12-15 CN CN201680079249.3A patent/CN108472324A/zh active Pending
- 2016-12-15 BR BR112018012262A patent/BR112018012262A2/pt not_active Application Discontinuation
- 2016-12-15 US US16/060,389 patent/US20180360977A1/en not_active Abandoned
- 2016-12-15 KR KR1020187020534A patent/KR20180089516A/ko not_active Withdrawn
- 2016-12-15 AU AU2016378387A patent/AU2016378387A1/en not_active Abandoned
- 2016-12-15 JP JP2018530797A patent/JP2019503348A/ja not_active Withdrawn
- 2016-12-15 CA CA3007819A patent/CA3007819A1/en not_active Abandoned
- 2016-12-15 MX MX2018007304A patent/MX2018007304A/es unknown
- 2016-12-15 EP EP16879902.1A patent/EP3393486A4/en not_active Withdrawn
- 2016-12-15 WO PCT/US2016/067042 patent/WO2017112528A2/en not_active Ceased
-
2018
- 2018-06-10 IL IL259919A patent/IL259919A/en unknown
- 2018-06-11 ZA ZA2018/03875A patent/ZA201803875B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503348A5 (cg-RX-API-DMAC7.html) | ||
| Alconcel et al. | FDA-approved poly (ethylene glycol)–protein conjugate drugs | |
| US8426357B2 (en) | Multimeric conjugate | |
| TW570802B (en) | Improved interferon polymer conjugates | |
| Roberts et al. | Chemistry for peptide and protein PEGylation | |
| CN1088721C (zh) | 干扰素结合物 | |
| DK2209494T3 (en) | New conjugated proteins and peptides | |
| CN101636414B (zh) | 聚乙二醇修饰的干扰素α2b及其制备方法和应用 | |
| TWI364295B (en) | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity | |
| JP2016526014A5 (cg-RX-API-DMAC7.html) | ||
| US20060051315A1 (en) | Polymers for delivering peptides and small molecules in vivo | |
| JP2014516993A5 (cg-RX-API-DMAC7.html) | ||
| Podobnik et al. | Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate | |
| Xue et al. | Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally monoPEGylated staphylokinase | |
| JP2007533665A (ja) | 新規ｇ−ｃｓｆ結合体 | |
| Bhawani et al. | Polymer based protein therapeutics | |
| EP2196475B1 (en) | INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION | |
| JP2006521372A (ja) | 生物学的活性物質と生体適合性高分子の１：１接合体、この製造方法とこれを含む薬学組成物 | |
| JP2008543304A (ja) | ヒト顆粒球コロニー刺激因子イソ型（ＨｕｍａｎＧｒａｎｕｌｏｃｙｔｅ−ＣｏｌｏｎｙＳｔｉｍｕｌａｔｉｎｇＦａｃｔｏｒＩｓｏｆｏｒｍｓ） | |
| CN1673230A (zh) | 重组人复合干扰素－聚乙二醇偶联物的制备及其偶联产物 | |
| CN101491682A (zh) | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 | |
| Chang et al. | A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b | |
| TW200426155A (en) | Activated polyethylene glycol esters | |
| KR20020067105A (ko) | 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체 | |
| Katre | Site-specific polymer–protein conjugates by Cys mutation |